ViV-TAVR Yields Improved Survival vs. Redo SAVR in Short Term, but Redo SAVR Gains Ground Over Time
In the largest propensity-score-matched comparison to date of patients who underwent valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) and those who underwent redo surgical aortic valve replacement (SAVR) for degenerated bioprostheses, ViV-TAVR was associated with a lower rate of all-cause mortality at 30 days but similar long-term mortality.